The Enhanced Liver Fibrosis (ELF) TestAssess the risk of NAFLD/NASH progression and liver-related events with a simple blood test

ELF Literature Compendium

The ELF™ Test* available on the Atellica® IM Analyzer and ADVIA Centaur® Immunoassay systems is a non-invasive blood test that measures three direct markers of fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). The ELF Test, in conjunction with other laboratory and clinical findings, can be used to assess the risk of progression to cirrhosis and liver-related clinical events (LREs) in patients with chronic liver disease.1

  • Access non-invasive testing with a simple blood test available to all healthcare practitioners and patients, including those with type 2 diabetes mellitus and obesity.2,3
  • Improve patient care by identifying non-alcoholic fatty liver disease (NAFLD) patients and stratifying those at risk of progressing to cirrhosis and LREs.1
  • Enhance prognostic patient management with a test that has been shown to outperform biopsy for the risk assessment of progression to cirrhosis and LREs.1

The performance of the ELF Test for liver fibrosis has been well-established in scientific literature, and ease of testing and interpretation support routine clinical use as an alternative to invasive biopsy.

The ELF literature compendium highlights a small subset of the extensive number of ELF publications and introduces the clinical utility of the ELF Test.

Subscription Button Icon

Keep up to date on the latest trends in healthcare. Read about current developments, new products and upcoming events.